Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients

Figure 1 The levels of serum tryptase (A) and vascular endothelial growth factor (B) in patients. A: Shows changes between serum tryptase levels before trans-arterial chemoembolization (TACE) (blue line) and serum tryptase levels after TACE (red line). A clear decreased concentration is showed for each patient after TACE; B: Shows changes between serum vascular endothelial growth factor (VEGF) levels before TACE (blue line) and serum VEGF levels after TACE (red line). A clear increased concentration is showed for each patient after vascular endothelial growth factor.

Figure 2 Serum tryptase (A) and trans-arterial chemoembolization (B) levels before TACE. A: Shows a strong correlation between serum tryptase levels before trans-arterial chemoembolization (TACE) and serum tryptase levels after TACE, in that a decreased tryptase levels is always present for each patient; B: Shows a good correlation between serum VEGF levels before TACE and serum VEGF levels after TACE, in that an increased VEGF levels is always present for each patient.